ArticleMedicine2026
Serum HMGB1 levels in elderly patients undergoing general anesthesia with dexmedetomidine and its correlation with early postoperative cognitive dysfunction.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This prospective cohort study investigated the effect of dexmedetomidine on serum High mobility group box 1 (HMGB1) levels in elderly patients after general anesthesia and its correlation with early cognitive dysfunction. A total of 108 elderly patients undergoing general surgery from January 2021 to December 2022 were recruited. Among them, 61 received dexmedetomidine, while the rest received normal saline. Serum levels of HMGB1, CRP, IL-6, and IL-1β were measured preoperatively and at 6, 24, and 72 hours, as well as 7 days postoperatively. Mini-Mental State Examination (MMSE) scores and clinical data were collected. Statistical analysis was performed using SPSS with P < .05 considered significant. The dexmedetomidine group had significantly higher MMSE scores at 24 hours postoperatively. Serum levels of HMGB1, IL-6, and IL-1β were lower in the dexmedetomidine group at all time points. Patients with MMSE < 27 had significantly higher HMGB1, IL-6, and IL-1β levels. HMGB1 at 6 hours postsurgery showed potential as a biomarker for early cognitive impairment. Additionally, HR at T3, MAP at T3, HMGB1, IL-6, IL-1β, and dexmedetomidine treatment were identified as risk factors for early cognitive impairment. Dexmedetomidine reduced serum HMGB1, IL-6, and IL-1β levels in elderly patients after general anesthesia. HMGB1 may serve as a risk factor and potential biomarker for early postoperative cognitive dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.